Literature DB >> 2645044

New vistas for leucovorin in cancer chemotherapy.

W A Bleyer1.   

Abstract

With a resurgence of interest in leucovorin calcium (LV), many questions about its role in cancer chemotherapy are being asked again. How does it modulate 5-fluorouracil (5-FU) therapy? Can it potentiate the cytotoxicity of 5-FU more in malignant than in normal cells? Does it rescue tumor cells from high-dose methotrexate (MTX) more than it does normal cells? How should LV rescue be individualized to maximize the therapeutic index? When can LV be administered orally, and how can LV rescue be conducted at home? When is LV rescue necessary, and what toxicities occur when it is inadequate? Some answers to these questions are provided in this review.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2645044     DOI： 10.1002/1097-0142(19890315)63:6+<995::aid-cncr2820631302>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  13 in total

1.  In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.

Authors:  Y Sugimoto; Y Ohe; K Nishio; T Ohmori; Y Fujiwara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity.

Authors:  Silas W Smith; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2008-06

3.  Rapid chemosensitivity assay with human normal and tumor cells in vitro.

Authors:  E Borenfreund; H Babich; N Martin-Alguacil
Journal:  In Vitro Cell Dev Biol       Date:  1990-11

4.  Disposition of 5-formyl- and 5-methyltetrahydrofolic acid in serum after i.v. bolus of calcium folinate: pharmacokinetic drug interaction with preadministered interferon-alpha-2b.

Authors:  M J Czejka; J Schüller; C Weiss; S Bandak; B Meyer; D Simon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

5.  5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.

Authors:  D Brohée
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

6.  Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; A E Sieder; G Locker; M F Gnant; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1994-03       Impact factor: 4.335

7.  Pharmacokinetic comparison of leucovorin and levoleucovorin.

Authors:  J Zittoun; A P Tonelli; J Marquet; E De Gialluly; C Hancock; A Yacobi; J B Johnson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  The practical use of methotrexate in psoriasis.

Authors:  J P Tung; H I Maibach
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

9.  The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.

Authors:  S Kase; T Kubota; M Watanabe; T Takahara; T Takeuchi; H Yamaguchi; T Furukawa; T Teramoto; S Kodaira; K Ishibiki
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

Review 10.  Clinical significance of cellular resistance in tumours to cytotoxic chemotherapy and radiotherapy.

Authors:  M Pomeroy; M Moriarty
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.